US4315851A
(en)
*
|
1978-12-29 |
1982-02-16 |
Kureha Kagaku Kogyo Kabushiki Kaisha |
Pharmaceutical composition having antitumor activity
|
JPS5616418A
(en)
*
|
1979-07-20 |
1981-02-17 |
Teijin Ltd |
Antitumor protein complex and its preparation
|
EP0044167A3
(fr)
*
|
1980-07-14 |
1982-04-21 |
The Regents Of The University Of California |
Agent cytotoxique dirigé par un anticorps
|
US4440747A
(en)
*
|
1980-09-30 |
1984-04-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease
|
JPS57106626A
(en)
*
|
1980-12-22 |
1982-07-02 |
Teijin Ltd |
Cytotoxic protein complex and its preparation
|
JPS57106625A
(en)
*
|
1980-12-22 |
1982-07-02 |
Teijin Ltd |
Cytotoxic protein complex and its preparation
|
FI820020L
(fi)
*
|
1981-01-12 |
1982-07-13 |
Lilly Industries Ltd |
Immunoglobulinkonjugater
|
SE8102193L
(sv)
*
|
1981-04-06 |
1982-10-07 |
Pharmacia Ab |
Terapeutiskt aktiv organisk forening och dess anvendning
|
SE8102194L
(sv)
*
|
1981-04-06 |
1982-10-07 |
Pharmacia Ab |
Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
|
FR2504010B1
(fr)
*
|
1981-04-15 |
1985-10-25 |
Sanofi Sa |
Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
|
JPS5874614A
(ja)
*
|
1981-10-30 |
1983-05-06 |
Teijin Ltd |
蛋白複合体及びその製造法
|
FR2516794B1
(fr)
*
|
1981-11-20 |
1985-10-25 |
Sanofi Sa |
Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
|
US5292668A
(en)
*
|
1981-12-21 |
1994-03-08 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US4444878A
(en)
*
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US5202252A
(en)
*
|
1982-03-05 |
1993-04-13 |
Houston Biotechnology Inc. |
Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction
|
FR2522968B1
(fr)
*
|
1982-03-10 |
1986-03-28 |
Sanofi Sa |
Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine
|
FR2523445A1
(fr)
*
|
1982-03-17 |
1983-09-23 |
Sanofi Sa |
Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
|
WO1983004026A1
(fr)
*
|
1982-05-11 |
1983-11-24 |
Genefusion S.A. |
Agent cytotoxique
|
US4468382A
(en)
*
|
1982-07-15 |
1984-08-28 |
New England Medical Center, Inc. |
Polypeptide-toxin hybrid protein
|
US4520226A
(en)
*
|
1982-07-19 |
1985-05-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
|
US4500637A
(en)
*
|
1982-07-19 |
1985-02-19 |
The United States Of America As Represented By The Department Of Health And Human Services |
Prevention of graft versus host disease following bone marrow transplantation
|
US4485093A
(en)
*
|
1982-08-13 |
1984-11-27 |
Runge Richard G |
Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
|
JPS59116232A
(ja)
*
|
1982-12-24 |
1984-07-05 |
Teijin Ltd |
細胞毒性複合体及びその製造法
|
US4916213A
(en)
*
|
1983-02-22 |
1990-04-10 |
Xoma Corporation |
Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
|
JPS59186924A
(ja)
*
|
1983-04-08 |
1984-10-23 |
Kureha Chem Ind Co Ltd |
ヒト免疫グロブリン結合抗腫瘍剤
|
US4664911A
(en)
*
|
1983-06-21 |
1987-05-12 |
Board Of Regents, University Of Texas System |
Immunotoxin conjugates employing toxin B chain moieties
|
GB2142428A
(en)
*
|
1983-06-23 |
1985-01-16 |
Erba Farmitalia |
Adenocarcinoma related antigenic determinants and antibodies specific thereto
|
GB2148299B
(en)
*
|
1983-09-01 |
1988-01-06 |
Hybritech Inc |
Antibody compositions of therapeutic agents having an extended serum half-life
|
US5169774A
(en)
*
|
1984-02-08 |
1992-12-08 |
Cetus Oncology Corporation |
Monoclonal anti-human breast cancer antibodies
|
DE3584486D1
(de)
*
|
1984-02-08 |
1991-11-28 |
Cetus Corp |
Toxinkonjugate.
|
US4753894A
(en)
*
|
1984-02-08 |
1988-06-28 |
Cetus Corporation |
Monoclonal anti-human breast cancer antibodies
|
US4894443A
(en)
*
|
1984-02-08 |
1990-01-16 |
Cetus Corporation |
Toxin conjugates
|
CA1314245C
(fr)
*
|
1984-05-23 |
1993-03-09 |
Franz Jansen |
Methode de preparation de conjugues formes d'un ionophore carboxylique monovalent associe par une liaison de covalence a une macromolecule et utiles comme agents de potentialisation d'immunotoxines
|
US4670563A
(en)
*
|
1984-06-20 |
1987-06-02 |
Sanofi |
Imidazolides as intermediates for the synthesis of cytotoxic conjugates
|
FR2566271B1
(fr)
*
|
1984-06-20 |
1986-11-07 |
Sanofi Sa |
Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
|
PT80662B
(en)
*
|
1984-06-20 |
1986-12-09 |
Sanofi Sa |
Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
|
US6808901B1
(en)
*
|
1984-09-03 |
2004-10-26 |
Celltech R&D Limited |
Production of chimeric antibodies
|
US4590071A
(en)
*
|
1984-09-25 |
1986-05-20 |
Xoma Corporation |
Human melanoma specific immunotoxins
|
AU585940B2
(en)
*
|
1984-09-25 |
1989-06-29 |
Xoma Corporation |
Lectin immunotoxins
|
US5185434A
(en)
*
|
1985-02-13 |
1993-02-09 |
Sanofi |
Prolonged-action immunotoxins containing a glycopeptide constituent which inactivates ribosomes, modified on its polysaccharide units
|
FR2577135B1
(fr)
*
|
1985-02-13 |
1989-12-15 |
Sanofi Sa |
Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
|
US4698420A
(en)
*
|
1985-02-25 |
1987-10-06 |
Xoma Corporation |
Antibody hybrid molecules and process for their preparation
|
WO1986005098A1
(fr)
*
|
1985-03-04 |
1986-09-12 |
Dana-Farber Cancer Institute, Inc. |
Immunotoxine et procede de production
|
US4888415A
(en)
*
|
1985-03-04 |
1989-12-19 |
Dana-Farber Cancer Institute, Inc. |
Gelonin immunotoxin
|
US4689311A
(en)
*
|
1985-09-30 |
1987-08-25 |
Rhode Island Hospital |
Screening antibodies for capacity to deliver toxin to target cells
|
US4731439A
(en)
*
|
1985-11-22 |
1988-03-15 |
Oncogen |
Snake venom growth arresting peptide
|
US4962188A
(en)
*
|
1985-12-06 |
1990-10-09 |
Cetus Corporation |
Recombinant ricin toxin A chain conjugates
|
US4911911A
(en)
*
|
1985-12-20 |
1990-03-27 |
Sanofi |
Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
|
IL80973A
(en)
*
|
1985-12-20 |
1992-08-18 |
Sanofi Sa |
Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
|
EP0252951A4
(fr)
*
|
1986-01-06 |
1988-09-07 |
Univ Melbourne |
Conjugues technetium-anticorps.
|
US4689401A
(en)
*
|
1986-03-06 |
1987-08-25 |
Cetus Corporation |
Method of recovering microbially produced recombinant ricin toxin a chain
|
US5242823A
(en)
*
|
1986-03-07 |
1993-09-07 |
International Genetic Engineering, Inc. |
Cloning of the 38kd Mycoplasma hyorhinis regression-associated antigen
|
US4748112A
(en)
*
|
1986-03-07 |
1988-05-31 |
International Genetic Engineering, Inc. |
Methods and compositions relating to regression-associated antigens
|
US4877868A
(en)
*
|
1986-03-12 |
1989-10-31 |
Neorx Corporation |
Radionuclide antibody coupling
|
WO1987005515A1
(fr)
*
|
1986-03-20 |
1987-09-24 |
Dana-Farber Cancer Institute, Inc. |
Complexe de lectine et sonde et procede de production
|
US5239062A
(en)
*
|
1986-03-20 |
1993-08-24 |
Dana-Farber Cancer Institute, Inc. |
Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
|
US5395924A
(en)
*
|
1986-03-20 |
1995-03-07 |
Dana-Farber Cancer Institute, Inc. |
Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
|
US4880935A
(en)
*
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
FR2601680B1
(fr)
*
|
1986-07-15 |
1990-06-29 |
Sanofi Sa |
Inhibiteur de la synthese proteique, procede d'isolement, utilisation et compositions pharmaceutiques en contenant
|
US4771128A
(en)
*
|
1986-10-10 |
1988-09-13 |
Cetus Corporation |
Method of purifying toxin conjugates using hydrophobic interaction chromatography
|
US4871350A
(en)
*
|
1986-11-04 |
1989-10-03 |
Baylor College Of Medicine |
Methods and compositions for preventing secondary cataracts
|
US5616122A
(en)
*
|
1986-11-04 |
1997-04-01 |
Baylor College Of Medicine |
Methods and compositions for preventing secondary cataracts
|
US5055291A
(en)
*
|
1986-11-04 |
1991-10-08 |
Baylor College Of Medicine |
Compositions for preventing secondary cataracts
|
US5158893A
(en)
*
|
1986-12-11 |
1992-10-27 |
Peralta Cancer Research Institute |
Methods and compositions for screening carcinomas
|
US5149528A
(en)
*
|
1987-04-10 |
1992-09-22 |
Zymogenetics, Inc. |
Cytotoxic protein from Trichosanthes kirilowii
|
US4985541A
(en)
*
|
1987-04-10 |
1991-01-15 |
Zymogenetics, Inc. |
Novel cytotoxic protein
|
US5591829A
(en)
*
|
1987-05-29 |
1997-01-07 |
Matsushita; Shuzo |
Antibodies modified with toxic substance
|
US4865841A
(en)
*
|
1987-10-23 |
1989-09-12 |
Imre Corporation |
Methods and compositions for transient elimination of humoral immune antibodies
|
JPH0535249Y2
(fr)
*
|
1988-03-31 |
1993-09-07 |
|
|
WO1989012624A2
(fr)
*
|
1988-06-14 |
1989-12-28 |
Cetus Corporation |
Agents de couplage et conjugues lies a des disulfures a empechement sterique prepares a partir de tels agents
|
US5241078A
(en)
*
|
1988-06-14 |
1993-08-31 |
Cetus Oncology |
Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
|
US5171563A
(en)
*
|
1988-09-30 |
1992-12-15 |
Neorx Corporation |
Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
|
US5162218A
(en)
*
|
1988-11-18 |
1992-11-10 |
The Regents Of The University Of California |
Conjugated polypeptides and methods for their preparation
|
WO1991010742A1
(fr)
*
|
1990-01-16 |
1991-07-25 |
Replgien Corporation |
Anticorps monoclonal specifique de l'epitope non-immunodominant de l'enveloppe proteinique du vih
|
US5191066A
(en)
*
|
1990-12-07 |
1993-03-02 |
Abbott Laboratories |
Site-specific conjugation of immunoglobulins and detectable labels
|
AU654563B2
(en)
*
|
1991-07-24 |
1994-11-10 |
Imperial Chemical Industries Plc |
Proteins
|
US5578706A
(en)
*
|
1993-11-04 |
1996-11-26 |
Board Of Regents, The University Of Texas |
Methods and compositions concerning homogenous immunotoxin preparations
|
US5690935A
(en)
*
|
1995-01-13 |
1997-11-25 |
Regents Of The University Of Minnesota |
Biotherapy of cancer by targeting TP-3/P80
|
US6146628A
(en)
*
|
1995-07-11 |
2000-11-14 |
Regents Of The University Of Minnesota And Rutgers |
Biotherapeutic agents comprising recombinant PAP and PAP mutants
|
ZA9711548B
(en)
*
|
1996-12-24 |
1999-06-23 |
Res Dev Foundation |
Ricin inhibitors and methods for use thereof
|
US6673914B1
(en)
|
1998-01-22 |
2004-01-06 |
John Wayne Cancer Institute |
Human tumor-associated gene
|
ES2533255T3
(es)
|
1998-07-13 |
2015-04-08 |
Board Of Regents, The University Of Texas System |
Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer
|
DE69934903T2
(de)
*
|
1998-11-10 |
2007-10-18 |
Emory University |
Mitogene regulatoren
|
PT1210428E
(pt)
|
1999-08-23 |
2015-07-21 |
Genetics Inst Llc |
Pd-1, um recetor para b7-4 e suas utilizações
|
GB9926875D0
(en)
*
|
1999-11-12 |
2000-01-12 |
Microbiological Research Agenc |
Use of lytic toxins and toxin conjugates
|
AU5003001A
(en)
|
2000-03-06 |
2001-09-17 |
Univ Kentucky Res Found |
Methods to impair hematologic cancer progenitor cells and compounds related thereto
|
US8163289B2
(en)
*
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
CA2437958C
(fr)
|
2001-03-09 |
2018-10-30 |
University Of Chicago |
Proteines hybrides d'immunoglobulines polymeriques ciblant des recepteurs fc.gamma. a faible affinite
|
WO2002079499A1
(fr)
|
2001-04-02 |
2002-10-10 |
Wyeth |
Le pd-1, recepteur du b7-4, et ses utilisations
|
US6846484B2
(en)
|
2001-12-28 |
2005-01-25 |
Regents Of The University Of Minnesota |
DTAT fusion toxin
|
US20050095627A1
(en)
*
|
2003-09-03 |
2005-05-05 |
The Salk Institute For Biological Studies |
Multiple antigen detection assays and reagents
|
WO2007025166A2
(fr)
*
|
2005-08-25 |
2007-03-01 |
Repair Technologies, Inc. |
Dispositifs, compositions et methodes de protection et de reparation de cellules et de tissus
|
FR2900341B1
(fr)
|
2006-04-27 |
2012-09-14 |
Centre Nat Rech Scient |
Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
|
US8163279B2
(en)
|
2007-04-13 |
2012-04-24 |
Stemline Therapeutics, Inc. |
IL3Rα antibody conjugates and uses thereof
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
WO2009141687A1
(fr)
*
|
2008-05-22 |
2009-11-26 |
Centre National De La Recherche Scientifique (Cnrs) |
Nouveaux composés optiquement purs pour une efficacité thérapeutique améliorée
|
GB0909904D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Product
|
GB0909906D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Antibodies
|
GB201002238D0
(en)
|
2010-02-10 |
2010-03-31 |
Affitech As |
Antibodies
|
CN103338782A
(zh)
|
2010-10-04 |
2013-10-02 |
国家科学研究中心 |
包含表面核仁素的多价合成配体和糖胺聚糖的组合物
|
GB201020738D0
(en)
|
2010-12-07 |
2011-01-19 |
Affitech Res As |
Antibodies
|
EP3613765A1
(fr)
|
2012-08-03 |
2020-02-26 |
Dana-Farber Cancer Institute, Inc. |
Anticorps contre le molécule de guidage répulsive b (rgmb)
|
AU2014241442B2
(en)
|
2013-03-14 |
2018-11-15 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to GREM 1
|
EP3293275B1
(fr)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions et procedes d'identification,d'evaluation, de prevention et de traitement du cancer en utilisant des isoformes pd-l1
|
EP3757130A1
(fr)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Méthodes de traitement de cancers hématologiques
|
WO2016094273A1
(fr)
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Procédés de régulation à la hausse des réponses immunitaires à l'aide de combinaisons d'agents anti-rgmb et d'agents anti-pd-1
|
WO2017066561A2
(fr)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Modulation de pd-1 des lymphocytes t régulateurs pour réguler les réponses immunitaires effectrices des lymphocytes t
|
KR20190080825A
(ko)
|
2016-03-21 |
2019-07-08 |
다나-파버 캔서 인스티튜트 인크. |
T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도
|
WO2018044640A1
(fr)
|
2016-08-29 |
2018-03-08 |
Regeneron Pharmaceuticals, Inc. |
Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
|
TW202311284A
(zh)
|
2017-01-03 |
2023-03-16 |
美商再生元醫藥公司 |
抗金黃色葡萄球菌溶血素a毒素之人類抗體
|
WO2020251924A1
(fr)
|
2019-06-12 |
2020-12-17 |
Regeneron Pharmaceuticals, Inc. |
Anticorps humains dirigés contre la protéine morphogénétique osseuse 6
|
CN116964088A
(zh)
|
2021-01-25 |
2023-10-27 |
里珍纳龙药品有限公司 |
用于治疗肺动脉高压(pah)的抗pdgf-b抗体和使用方法
|